643 related articles for article (PubMed ID: 33914256)
1. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
[TBL] [Abstract][Full Text] [Related]
2. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin
Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K
BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C
Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab biosimilar candidate TAB008 compared to Avastin
Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F
BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L; Rangel JDG; Cil T; Li X; Cicin I; Shen Y; Liu Z; Ozyilkan O; Igor B; Chen J; Oleksandr K; Chen Z; Zhang H; Fu Z; Dong Q; Song S; Yu JC; Zhang L
Cancer Med; 2023 Nov; 12(22):20847-20863. PubMed ID: 37935428
[TBL] [Abstract][Full Text] [Related]
8. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
[TBL] [Abstract][Full Text] [Related]
9. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
Verschraegen C; Andric Z; Moiseenko F; Makharadze T; Shevnya S; Oleksiienko A; Yañez Ruiz E; Kim S; Ahn K; Park T; Park S; Ju H; Ohe Y
BioDrugs; 2022 Nov; 36(6):749-760. PubMed ID: 36169807
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Thatcher N; Goldschmidt JH; Thomas M; Schenker M; Pan Z; Paz-Ares Rodriguez L; Breder V; Ostoros G; Hanes V
Clin Cancer Res; 2019 Apr; 25(7):2088-2095. PubMed ID: 30617139
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
[TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D
Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
14. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Eto T; Karasuyama Y; González V; Del Campo García A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
[TBL] [Abstract][Full Text] [Related]
15. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
Miguel-Lillo B; Sánchez-Vidaurre S; Pérez Díaz L; Paravisini A
Pharmacol Res Perspect; 2023 Dec; 11(6):e01139. PubMed ID: 37920875
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
18. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
[TBL] [Abstract][Full Text] [Related]
20. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
